Zobrazeno 1 - 10
of 760
pro vyhledávání: '"Anti-drug antibody"'
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
ABSTRACTThe surge in the clinical use of therapeutic antibodies has reshaped the landscape of pharmaceutical therapy for many diseases, including rare and challenging conditions. However, the administration of exogenous biologics could potentially tr
Externí odkaz:
https://doaj.org/article/35791c01bb7b437085106c688356d180
Autor:
Hui-An Chen, Rai-Hseng Hsu, Ching-Ya Fang, Ankit K. Desai, Ni-Chung Lee, Wuh-Liang Hwu, Fuu-Jen Tsai, Priya S. Kishnani, Yin-Hsiu Chien
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionPompe disease, a lysosomal storage disorder, is characterized by acid α-glucosidase (GAA) deficiency and categorized into two main subtypes: infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD). The primary treatment,
Externí odkaz:
https://doaj.org/article/d580f3c7d33d45768fcfbe1d68b78034
Autor:
Anna Spreafico, Eva Muñoz Couselo, Anja Irmisch, Juliana Bessa, George Au-Yeung, Oliver Bechter, Inge Marie Svane, Miguel F. Sanmamed, Valentina Gambardella, Meredith McKean, Margaret Callahan, Reinhard Dummer, Christian Klein, Pablo Umaña, Nicole Justies, Florian Heil, Linda Fahrni, Eugenia Opolka-Hoffmann, Inja Waldhauer, Conrad Bleul, Roland F. Staack, Vaios Karanikas, Stephen Fowler
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionAlthough checkpoint inhibitors (CPIs) have improved outcomes for patients with metastatic melanoma, those progressing on CPIs have limited therapeutic options. To address this unmet need and overcome CPI resistance mechanisms, novel immun
Externí odkaz:
https://doaj.org/article/1b6cf328c2214d24859fac4cbcd710e0
Autor:
Helena Cerutti, Giulia Tesi, Francesco Petrini, Tommaso Bandini, Alessandra Cartocci, Andrea Ianniello, Alessia Bogi, Chiara Muzzi, Alessandra Brogi
Publikováno v:
Practical Laboratory Medicine, Vol 39, Iss , Pp e00374- (2024)
Objective: To convert manual ELISA kits to fully automated immunoassays that quantify serum drug levels and anti-drug antibodies levels of infliximab and adalimumab (CHORUS Promonitor kits). Desing and methods: CHORUS Promonitor INFLIXIMAB, CHORUS Pr
Externí odkaz:
https://doaj.org/article/f8ca9272d0ea42a6bfcd1fc94aa9938f
Autor:
Yoshiyuki Arata, Shigeki Motoyama, Mariko Yano, Tatsuya Ikuno, Shunsuke Ito, Tomochika Matsushita, Akira Takeiri, Yukari Nishito, Nami Yabuki, Hideaki Mizuno, Zenjiro Sampei, Masayuki Mishima, Masaki Honda, Jumpei Kiyokawa, Hiromi Suzuki, Shuichi Chiba, Mitsuyasu Tabo, Chiyomi Kubo
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTTherapeutic antibodies sometimes elicit anti-drug antibodies (ADAs) that can affect efficacy and safety. Engineered antibodies that contain artificial amino acid sequences are potentially highly immunogenic, but this is currently difficult to
Externí odkaz:
https://doaj.org/article/9c8b83e3cca74382a102aa8a0b0f06ad
Publikováno v:
Heliyon, Vol 9, Iss 11, Pp e21858- (2023)
Infliximab and its anti-drug antibody (ADA) serum concentrations exhibit a strong correlation with clinical response and loss of response. The use of therapeutic drug monitoring to measure the concentration of infliximab and ADA can facilitate clinic
Externí odkaz:
https://doaj.org/article/14039e8e193e42c8b817143e5c1ed08a
Autor:
Katherine H. Kim, Ankit K. Desai, Erika R. Vucko, Tracy Boggs, Priya S. Kishnani, Barbara K. Burton
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 36, Iss , Pp 100981- (2023)
A late-onset Pompe disease patient developed high sustained antibody titers (HSAT) of ≥51,200 after 11+ years on alglucosidase alfa and previous tolerance. There was a corresponding worsening of motor function and rise in urinary glucose tetrasacch
Externí odkaz:
https://doaj.org/article/a4e5cd8daf564e5ba10738d304447e3f
Autor:
Hideo Sakane, Koichi Okamura, Makoto Inoue, Hiroshi Inoue, Yukio Yonemoto, Hirofumi Mitomi, Kosei Tsuchida, Takahito Suto, Tetsuya Kaneko, Hirotaka Chikuda
Publikováno v:
BMC Rheumatology, Vol 6, Iss 1, Pp 1-5 (2022)
Abstract Background This study evaluated the existence of anti-drug antibodies (ADAs) before and 52 weeks after switching from intravenous infliximab (IFX) to intravenous CT-P13 in patients with rheumatoid arthritis (RA). Methods We performed a prosp
Externí odkaz:
https://doaj.org/article/5da91fcfa76d46089e24c7840b717d2c
Autor:
Lin-Zhi Chen, David Roos, Elsy Philip, Emily G. Werth, Stephanie Kostuk, Hongbin Yu, Holger Fuchs
Publikováno v:
Pharmaceuticals, Vol 17, Iss 2, p 193 (2024)
BI-X, a therapeutic protein under development for the treatment of human ocular disease via intravitreal administration, binds to its therapeutic targets and endogenous albumin in the vitreous humor. A monkey ocular pharmacokinetic (PK) study followi
Externí odkaz:
https://doaj.org/article/7a011e49b1bc40a7b8551599e66b1f2b
Autor:
Yimin Tao, Wei Lu, Jinli Gao, Shuangshuang Yang, Chaoyi Ruan, Yingying Hou, Jing Lu, Junjiu Xu, Jianjian Zhang, Stephanie Pasas-Farmer, Qiuping Qin, Likun Gong
Publikováno v:
Molecules, Vol 29, Iss 3, p 572 (2024)
Background: The development of an anti-drug antibody (ADA)-tolerant pharmacokinetic (PK) assay is important when the drug exposure is irrelevant to toxicity in the presence of ADA. We aimed to develop and validate an ADA-tolerant assay for an exateca
Externí odkaz:
https://doaj.org/article/3c75d75cd3584f4da028a319053008f7